Intravacc uses cookies to record web statistics of visitors to its website. A cookie is a small text file that is stored on your computer to help us
identify you during subsequent visits to our website. Do you accept this?

Slider nummer 1

Meet Intravacc

Intravacc has a long history in developing vaccines. It promotes public health by developing vaccines from the laboratory to clinical study in man. To achieve this mission, our aim is to substantially reduce development risks and costs of new vaccines by bridging the translational gap between laboratory bench and market.

Factsheets

Take a look at our factsheets to discover the variety of our research and development activities. 

View all factsheets

VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2)

European public and private organisations, including Intravacc, are collaborating in VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2) to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods.

For more information and full press release, follow link

Read more...

Replacing, reducing and refining the use animals in the lab

‘Will all laboratory animals be retired in 2040?’

Replacing, reducing and refining the use animals in the lab…. Throughout his career Prof. Dr. Coenraad Hendriksen worked on all aspects of the 3Rs, particularly in the vaccine field, and successfully developed variety of alternatives.

Read more...

A sustainable, good, affordable Hib vaccine for every child

With her doctoral research, TU Delft doctoral candidate Ahd Hamidi has made a major contribution to developing an innovative, scalable, affordable version of the Haemophilus influenzae (Hib) vaccine developed by Intravacc. This low-cost vaccine has now been used to protect 200 million children worldwide against Hib diseases such as meningitis, pneumonia, sepsis and otitis media. Hamidi has defended her dissertation at TU Delft on Thursday 3 March.

Read more...